Wanbury AGM approves cost auditor and re-appoints WTD beyond age 70

Management Changes View source PDF Explain this filing

WANBURY · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.6%Reaction day

₹226.20

prior close

₹226.45

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.3%-0.8% vs market

Pharmaceuticals peers, median of 171sector-0.0%-0.5% vs sector

On the reaction day the stock moved 0.8 pts less than Nifty Microcap 250 and 0.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.5

10m

+0.4

15m

+0.8

30m

+0.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.6+0.3-0.8-0.0-0.5

Next day

-1.1-1.3+0.2-1.3+0.3

-4.5-0.3-4.2-0.6-3.9

-13.3-0.6-12.8-1.6-11.7

-13.0-1.8-11.1-2.5-10.5

-16.0-1.8-14.2-2.7-13.4

-12.7-0.8-12.0-2.2-10.5

15d

-17.3-4.1-13.2-6.0-11.4

-25.3-9.4-15.9-9.1-16.2

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 171Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Wanbury held its 38th AGM on Sept 24, 2026. Shareholders approved the appointment of M/s ABK & Associates as Cost Auditor for FY 2026-27. They also re-appointed Mr. Mohan Kumar Rayana as Whole-time Director for five years (Aug 21, 2026 to Aug 20, 2031), allowing him to continue beyond age 70. Mr. Mohan holds a B.Pharm and has over 25 years of pharma industry experience in advisory and management roles.

Likely market impact

Routine governance approvals. WTD continuation beyond age 70 may draw mild governance attention from some institutional investors.